Avenue Therapeutics to participate in Type C FDA meeting for IV Tramadol

(24/7 MARKET NEWS) – Avenue Therapeutics, Inc. (NASDAQ: ATXI) is scheduled to participate in a Type C meeting with the FDA, today, to discuss a proposed study protocol to assess the risk of respiratory depression related to opioid stacking on intravenous tramadol (“IV Tramadol”) relative to an approved opioid analgesic and expects to provide an update on the outcome of the meeting in April 2023, following receipt of the meeting minutes from the FDA.

Avenue Therapeutics is trading at $1.15, up $0.11 (+10.58%), on 2.1 million premarket shares.

Its 52-week trading range is $0.983 to $16.65.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist